The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer
Open accessAbstract
Background & Aims Biomarkers are needed to identify patients at risk of tumor progression following chemoradiotherapy for localized esophageal cancer. These could improve identification of patients at risk for cancer progression and selection of therapy. Methods We performed deep sequencing (CAPP-Seq) analyses of plasma cell-free DNA collected from 45 patients before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes, and fixed esophageal tumor biopsies collected during esophagogastroduodenoscopy. Patients were treated from May 2010 through October 2015; 23 patients subsequently underwent esophagectomy and 22 did not undergo surgery. We also sequenced DNA from blood samples from 40 healthy individuals (controls). We analyzed 802 regions of 607 genes for single-nucleotide variants previously associated with esophageal adenocarcinoma or squamous cell carcinoma. Patients underwent imaging analyses 6–8 weeks after chemoradiotherapy and were followed for 5 years. Our primary aim was to determine whether detection of circulating tumor DNA (ctDNA) following chemoradiotherapy is associated with risk of tumor progression (growth of local, regional, or distant tumors, detected by imaging or biopsy). Results The median proportion of tumor-derived DNA in total cell-free DNA before treatment was 0.07%, indicating that ultrasensitive assays are needed for quantification and analysis of ctDNA from localized esophageal tumors. Detection of ctDNA following chemoradiotherapy was associated with tumor progression (hazard ratio, 18.7; P<.0001), formation of distant metastases (hazard ratio, 32.1; P<.0001), and shorter disease-specific survival times (hazard ratio, 23.1; P<.0001). A higher proportion of patients with tumor progression had new mutations detected in plasma samples collected after chemoradiotherapy than patients without progression (P=.03). Detection of ctDNA after chemoradiotherapy preceded radiographic evidence of tumor progression by an average of 2.8 months. Among patients who received chemoradiotherapy without surgery, combined ctDNA and metabolic imaging analysis predicted progression in 100% of patients with tumor progression, compared with 71% for only ctDNA detection and 57% for only metabolic imaging analysis (P<.001 for comparison of either technique to combined analysis). Conclusions In an analysis of cell-free DNA in blood samples from patients who underwent chemoradiotherapy for esophageal cancer, detection of ctDNA was associated with tumor progression, metastasis, and disease-specific survival. Analysis of ctDNA might be used to identify patients at highest risk for tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Self-citationAge-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Integrated genomic characterization of oesophageal carcinoma
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,821
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Stahl, M., Stuschke, M., Lehmann, N., Meyer, H.-J., Walz, M. K., Seeber, S., Klump, B., Budach, W., Teichmann, R., Schmitt, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.034 · Cited by 1,314
Bedenne, L., Michel, P., Bouché, O., Milan, C., Mariette, C., Conroy, T., Pezet, D., Roullet, B., Seitz, J.-F., Herr, J.-P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7118 · Cited by 1,244
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,099
Self-citationIdentification of genomic alterations in oesophageal squamous cell cancer
Song, Y., Li, L., Ou, Y., Gao, Z., Li, E., Li, X., Zhang, W., Wang, J., Xu, L., Zhou, Y., et al. (2014) · Nature · doi:10.1038/nature13176 · Cited by 1,083
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
Self-citationDulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 735
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 648
Self-citationBerger, A. C., Farma, J., Scott, W. J., Freedman, G., Weiner, L., Cheng, J. D., Wang, H., & Goldberg, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.017 · Cited by 505
Sausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R. J., Barrett, M. T., Anagnostou, V., Parpart-Li, S., Murphy, D., Kay Li, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms8686 · Cited by 484
Challenges of Guarantee-Time Bias
Giobbie-Hurder, A., Gelber, R. D., & Regan, M. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.5283 · Cited by 458
Comparative Genomic Analysis of Esophageal Adenocarcinoma and Squamous Cell Carcinoma
Agrawal, N., Jiao, Y., Bettegowda, C., Hutfless, S. M., Wang, Y., David, S., Cheng, Y., Twaddell, W. S., Latt, N. L., Shin, E. J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0189 · Cited by 381
Tie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K., Elsaleh, H., Kosmider, S., Wong, R., Yip, D., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315852 · Cited by 381
Westerterp, M., van Westreenen, H. L., Reitsma, J. B., Hoekstra, O. S., Stoker, J., Fockens, P., Jager, P. L., Van Eck-Smit, B. L. F., Plukker, J. T. M., van Lanschot, J. J. B., et al. (2005) · Radiology · doi:10.1148/radiol.2363041042 · Cited by 299
Donahue, J., Nichols, F. C., Li, Z., Schomas, D. A., Allen, M. S., Cassivi, S. D., Jatoi, A., Miller, R. C., Wigle, D. A., Shen, K. R., et al. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2008.11.001 · Cited by 280
Monjazeb, A. M., Riedlinger, G., Aklilu, M., Geisinger, K. R., Mishra, G., Isom, S. P., Clark, P. B., Levine, E. A., & Blackstock, A. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7702 · Cited by 132
Roedl, J. B., Colen, R. R., Holalkere, N.-S., Fischman, A. J., Choi, N. C., & Blake, M. A. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.06.014 · Cited by 124
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer
Vellayappan, B. A., Soon, Y. Y., Ku, G. Y., Leong, C. N., Lu, J. J., & Tey, J. C. S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010511.pub2 · Cited by 116
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
Findlay, J. M., Castro-Giner, F., Makino, S., Rayner, E., Kartsonaki, C., Cross, W. C. H., Kovac, M. B., Ulahannan, D., Palles, C., Gillies, R. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11111 · Cited by 104
Ueda, M., Iguchi, T., Masuda, T., Nakahara, Y., Hirata, H., Uchi, R., Niida, A., Momose, K., Sakimura, S., Chiba, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11409 · Cited by 77
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis
Creemers, A., Krausz, S., Strijker, M., van der Wel, M. J., Soer, E. C., Reinten, R. J. A., Besselink, M. G., Wilmink, J. W., van de Vijver, M. J., van Noesel, C. J. M., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.08.002 · Cited by 73
Jayachandran, P., Pai, R. K., Quon, A. S. W., Graves, E. E., Krakow, T. E., La, T. H., Loo, B. W., Koong, A. C., & Chang, D. T. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.12.029 · Cited by 65
Hsieh, C., Hsu, H., Chang, S., & Chen, Y.-J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122131 · Cited by 54
Luo, H., Li, H., Hu, Z., Wu, H., Liu, C., Li, Y., Zhang, X., Lin, P., Hou, Q., Ding, G., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.011 · Cited by 48
Self-citationLiquid biopsies in gastrointestinal malignancies: when is the big day?
Lopez, A., Harada, K., Kaya, D. M., Dong, X., Song, S., & Ajani, J. A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1403320 · Cited by 32
Quality of life assessment in esophagectomy patients
Alghamedi, A., Buduhan, G., Tan, L., Srinathan, S., Sulman, J., Darling, G. E., & Kidane, B. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.38 · Cited by 29
Cronin-Fenton, D. P., Sharp, L., Carsin, A., & Comber, H. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.011 · Cited by 28
Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma
Andolfo, I., Petrosino, G., Vecchione, L., Antonellis, P. D., Capasso, M., Montanaro, D., Gemei, M., Troncone, G., Iolascon, A., Orditura, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-126 · Cited by 26
Komatsu, S., Ichikawa, D., Hirajima, S., Takeshita, H., Shiozaki, A., Fujiwara, H., Kawaguchi, T., Miyamae, M., Konishi, H., Kubota, T., et al. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-3005-2 · Cited by 17
Openshaw, M. R., Richards, C. J., Guttery, D. S., Shaw, J., & Thomas, A. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1308824 · Cited by 12
Cited by
Gale, D., Heider, K., Ruiz-Valdepenas, A., Hackinger, S., Perry, M., Marsico, G., Rundell, V., Wulff, J., Sharma, G., Knock, H., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.007 · Cited by 335
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Self-citationBridging biological cfDNA features and machine learning approaches
Moser, T., Kühberger, S., Lazzeri, I., Vlachos, G., & Heitzer, E. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.01.004 · Cited by 133
Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques
Wen, X., Pu, H., Liu, Q., Guo, Z., & Luo, D. (2022) · Cancers · doi:10.3390/cancers14246025 · Cited by 99
Metadata
- Authors
- Azad, T. D., Chaudhuri, A. A., Fang, P., Qiao, Y., Esfahani, M. S., Chabon, J. J., Hamilton, E. G., Yang, Y. D., Lovejoy, A., Newman, A. M., Kurtz, D. M., Jin, M., Schroers-Martin, J., Stehr, H., Liu, C. L., Hui, A. B.-Y., Patel, V., Maru, D., Lin, S. H., Alizadeh, A. A., & Diehn, M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 158
- Issue
- 3
- Pages
- 494-505.e6
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2985165646
- Cited by
- 266
- References
- 39
- FWCI
- 24.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.